Program strategies and efficiencies

Over the years, Pharmetheus has contributed to the establishment and maintenance of a model-informed drug development (MIDD)-mindset within a wide range of pharmaceutical companies.

We have done so by enhancing collaboration across a variety of disciplines including statisticians, clinical pharmacologists, and clinicians.

These collaborations have underpinned the development of a quantitative framework where a variety of fit-for-purpose modeling approaches have been integrated to support and inform development program strategies and decisions most effectively and efficiently.

Cycle of activities underpinned by MIDD -study design, study execution, data analysis, information integration- leading to increase of knowledge

Greater efficiencies and untapped potential

Choosing a strategy on how to leverage data from different programs to better understand a disease, a clinical endpoint, or a placebo response can be a challenge and hinder efficiencies.

Establishing collaboration between quantitative approaches and functions is important but also context-of-use dependent.

Pharmetheus houses the relevant team experience and expertise to support you at these stages, and our tailored MIDD Pharmetheus Platform solutions help organizations build greater efficiencies, awareness, and source untapped potential.